Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 124

1.

Tumor-associated zinc finger mutations in the CTCF transcription factor selectively alter tts DNA-binding specificity.

Filippova GN, Qi CF, Ulmer JE, Moore JM, Ward MD, Hu YJ, Loukinov DI, Pugacheva EM, Klenova EM, Grundy PE, Feinberg AP, Cleton-Jansen AM, Moerland EW, Cornelisse CJ, Suzuki H, Komiya A, Lindblom A, Dorion-Bonnet F, Neiman PE, Morse HC 3rd, Collins SJ, Lobanenkov VV.

Cancer Res. 2002 Jan 1;62(1):48-52.

PMID:
11782357
[PubMed - indexed for MEDLINE]
Free Article
2.

A widely expressed transcription factor with multiple DNA sequence specificity, CTCF, is localized at chromosome segment 16q22.1 within one of the smallest regions of overlap for common deletions in breast and prostate cancers.

Filippova GN, Lindblom A, Meincke LJ, Klenova EM, Neiman PE, Collins SJ, Doggett NA, Lobanenkov VV.

Genes Chromosomes Cancer. 1998 May;22(1):26-36.

PMID:
9591631
[PubMed - indexed for MEDLINE]
3.

Regulatory factor interactions and somatic silencing of the germ cell-specific ALF gene.

Kim M, Li D, Cui Y, Mueller K, Chears WC, DeJong J.

J Biol Chem. 2006 Nov 10;281(45):34288-98. Epub 2006 Sep 11.

PMID:
16966320
[PubMed - indexed for MEDLINE]
Free Article
4.

Familial cases of point mutations in the XIST promoter reveal a correlation between CTCF binding and pre-emptive choices of X chromosome inactivation.

Pugacheva EM, Tiwari VK, Abdullaev Z, Vostrov AA, Flanagan PT, Quitschke WW, Loukinov DI, Ohlsson R, Lobanenkov VV.

Hum Mol Genet. 2005 Apr 1;14(7):953-65. Epub 2005 Feb 24.

PMID:
15731119
[PubMed - indexed for MEDLINE]
Free Article
5.

Physical and functional interaction between two pluripotent proteins, the Y-box DNA/RNA-binding factor, YB-1, and the multivalent zinc finger factor, CTCF.

Chernukhin IV, Shamsuddin S, Robinson AF, Carne AF, Paul A, El-Kady AI, Lobanenkov VV, Klenova EM.

J Biol Chem. 2000 Sep 22;275(38):29915-21.

PMID:
10906122
[PubMed - indexed for MEDLINE]
Free Article
6.

Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1.

Borel F, Barilla KC, Hamilton TB, Iskandar M, Romaniuk PJ.

Biochemistry. 1996 Sep 17;35(37):12070-6.

PMID:
8810912
[PubMed - indexed for MEDLINE]
7.

An exceptionally conserved transcriptional repressor, CTCF, employs different combinations of zinc fingers to bind diverged promoter sequences of avian and mammalian c-myc oncogenes.

Filippova GN, Fagerlie S, Klenova EM, Myers C, Dehner Y, Goodwin G, Neiman PE, Collins SJ, Lobanenkov VV.

Mol Cell Biol. 1996 Jun;16(6):2802-13.

PMID:
8649389
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

CTCF is a uniquely versatile transcription regulator linked to epigenetics and disease.

Ohlsson R, Renkawitz R, Lobanenkov V.

Trends Genet. 2001 Sep;17(9):520-7. Review.

PMID:
11525835
[PubMed - indexed for MEDLINE]
9.

Loss of imprinting of insulin-like growth factor-II in Wilms' tumor commonly involves altered methylation but not mutations of CTCF or its binding site.

Cui H, Niemitz EL, Ravenel JD, Onyango P, Brandenburg SA, Lobanenkov VV, Feinberg AP.

Cancer Res. 2001 Jul 1;61(13):4947-50.

PMID:
11431321
[PubMed - indexed for MEDLINE]
Free Article
10.

CTCF, a conserved nuclear factor required for optimal transcriptional activity of the chicken c-myc gene, is an 11-Zn-finger protein differentially expressed in multiple forms.

Klenova EM, Nicolas RH, Paterson HF, Carne AF, Heath CM, Goodwin GH, Neiman PE, Lobanenkov VV.

Mol Cell Biol. 1993 Dec;13(12):7612-24.

PMID:
8246978
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

The cancer-testis antigen BORIS phenocopies the tumor suppressor CTCF in normal and neoplastic cells.

Tiffen JC, Bailey CG, Marshall AD, Metierre C, Feng Y, Wang Q, Watson SL, Holst J, Rasko JE.

Int J Cancer. 2013 Oct 1;133(7):1603-13. doi: 10.1002/ijc.28184. Epub 2013 May 2.

PMID:
23553099
[PubMed - indexed for MEDLINE]
12.

Functional phosphorylation sites in the C-terminal region of the multivalent multifunctional transcriptional factor CTCF.

Klenova EM, Chernukhin IV, El-Kady A, Lee RE, Pugacheva EM, Loukinov DI, Goodwin GH, Delgado D, Filippova GN, León J, Morse HC 3rd, Neiman PE, Lobanenkov VV.

Mol Cell Biol. 2001 Mar;21(6):2221-34.

PMID:
11238955
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer.

Klenova EM, Morse HC 3rd, Ohlsson R, Lobanenkov VV.

Semin Cancer Biol. 2002 Oct;12(5):399-414. Review.

PMID:
12191639
[PubMed - indexed for MEDLINE]
14.

KRAB-independent suppression of neoplastic cell growth by the novel zinc finger transcription factor KS1.

Gebelein B, Fernandez-Zapico M, Imoto M, Urrutia R.

J Clin Invest. 1998 Dec 1;102(11):1911-9.

PMID:
9835615
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Inhibition of Wilms tumor 1 transactivation by bone marrow zinc finger 2, a novel transcriptional repressor.

Lee TH, Lwu S, Kim J, Pelletier J.

J Biol Chem. 2002 Nov 22;277(47):44826-37. Epub 2002 Sep 17.

PMID:
12239212
[PubMed - indexed for MEDLINE]
Free Article
16.

Negative transcriptional regulation mediated by thyroid hormone response element 144 requires binding of the multivalent factor CTCF to a novel target DNA sequence.

Awad TA, Bigler J, Ulmer JE, Hu YJ, Moore JM, Lutz M, Neiman PE, Collins SJ, Renkawitz R, Lobanenkov VV, Filippova GN.

J Biol Chem. 1999 Sep 17;274(38):27092-8.

PMID:
10480923
[PubMed - indexed for MEDLINE]
Free Article
17.

Isolation and characterization of a novel zinc-finger protein with transcription repressor activity.

Williams AJ, Khachigian LM, Shows T, Collins T.

J Biol Chem. 1995 Sep 22;270(38):22143-52.

PMID:
7673192
[PubMed - indexed for MEDLINE]
Free Article
18.

A region to the N-terminal side of the CTCF zinc finger domain is essential for activating transcription from the amyloid precursor protein promoter.

Vostrov AA, Taheny MJ, Quitschke WW.

J Biol Chem. 2002 Jan 11;277(2):1619-27. Epub 2001 Nov 8.

PMID:
11706010
[PubMed - indexed for MEDLINE]
Free Article
19.

Products of alternatively spliced transcripts of the Wilms' tumor suppressor gene, wt1, have altered DNA binding specificity and regulate transcription in different ways.

Wang ZY, Qiu QQ, Huang J, Gurrieri M, Deuel TF.

Oncogene. 1995 Feb 2;10(3):415-22.

PMID:
7845666
[PubMed - indexed for MEDLINE]
20.

DNA binding sites for putative methylation boundaries in the unmethylated region of the BRCA1 promoter.

Butcher DT, Mancini-DiNardo DN, Archer TK, Rodenhiser DI.

Int J Cancer. 2004 Sep 20;111(5):669-78.

PMID:
15252835
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk